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MetastasisPhase III clinical trials with cancer patients with the ﬁrst generation of synthetic MMP inhibitors (MMPIs)
failed due to inefﬁcacy and adverse side effects. These results were unexpected, given the wealth of pre-
clinical data implicating MMPs as cancer targets, but are attributable to the broad-spectrum activity of these
early MMPIs and the limited knowledge of the variety of biological functions of MMPs at the time they were
deployed. These experiences stimulated the development of a variety of highly speciﬁc synthetic MMPIs.
However, the bottle-neck is the identiﬁcation of true target-MMPs. Functional genetic approaches are being
complicated by the existence of the ‘protease web,’ i.e., the dynamic interconnectivity of MMPs and other
proteases, their inhibitors, and substrates that collectively establish homeostasis in signaling in healthy and
disease-afﬂicted tissue. Therefore, even speciﬁc MMP inhibition can result in seemingly unpredictable
induction of systemic protease web-associated modulations (spam), which can comprise metastasis-
promoting molecules such as other proteases and cytokines. Such undesired information in local proteolytic
networks or relayed systemically in the organism via the proteolytic internet needs to be understood and
deﬁned in order to design speciﬁc metastasis therapies employing highly speciﬁc MMPIs in combination
with spam-ﬁltering agents.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
There is ample evidence that matrix metalloproteinases (MMPs)
are associated with tumor progression [1], a feature that they share
withmany serine [2], cysteine [3], andaspartyl proteases [4]. Currently,
intensive research in theﬁeld is focusing onwhether or not someof the
24 human MMPs can be identiﬁed as targets for tumor therapies (see
other articles in this issue). The endeavor of exploiting proteases for
efﬁcient anti-metastatic therapy ismore than justiﬁed, because there is
still no decisive progress in the management of this late step of the
disease process.
The fact that broad-spectrumMMP inhibition induces adverse side
effects [5], including promotion of liver metastasis [6,7], has led to one
of themost important realizations since the failure of the clinical trials
with such agents: proteases, includingMMPs, are interconnected with
each other and their natural inhibitors in complicated proteolytic
networks [8]. They not only have path-clearing functions [9] but also
produce degradation products with important signaling function for
gene expression and cell behavior, their collective actions being
deﬁned as the ‘protease web’ [8]. In addition, at least one MMP has: +49 89 4140 6182.
(A. Krüger).
ll rights reserved.since been identiﬁed to have a clear anti-metastatic activity [10],
implying that the choice of a protease as a target requires information
on its function within the tumor ecosystem [11].
Progress has been made in the attempt to design highly speciﬁc
MMP inhibitors (MMPIs) [12,13]. However, before these are used in
earnest in the clinic, it is necessary to identify possible consequences
of their use in vivo in order to avoid the kind of problems encountered
with broad-spectrumMMPIs. The aim in this review is to point out the
occurrence of systemic protease web-associated modulation (spam)
in the environment of tumor cells that results from MMP inhibition,
and which in turn may promote metastasis. Analysis of spam in the
‘proteolytic internet’ within an organism [14] will reveal whether
MMPI-induced gene expression proﬁles in tissues have counter-
productive consequences or whether they are manageable by
combination therapy with drugs acting as spam-ﬁltering agents.
2. In vivo complexity spoils the straightforward approach
The original reports on MMPs as tumor-associated and tumor-
promoting enzymes [15] initiated the development of synthetic
broad-spectrumMMPIs as promising cancer drugs, intended to inhibit
the mortality-determining invasive steps of tumor progression [15].
Chemistry could easily provide solutions for this initial straightfor-
ward concept due to the uniform structural features of the zinc-
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generation of MMPIs consisted of peptidomimetic compounds that
interacted with the well-conserved structure within the catalytic
domain and often carried a hydroxamic acid moiety as zinc-binding
group [17]. Batimastat (BB-94), the ﬁrst MMPI evaluated in cancer
patients, and its orally bioavailable successor marimastat (BB-2516)
and other drugs such as GM6001 [18], MMI270 (CGS27023A) [19],
and GI129471 [12,20] belonged to this group. The disadvantage of the
strong zinc-binding group of these hydroxamate inhibitors was that it
can also potently inhibit other zinc-dependent metalloproteinases
such as the ADAMs (a disintegrin and metalloproteinase [21]) or even
metalloproteinases that lack signiﬁcant sequence homology with
MMPs [22]. In hindsight, it is surprising that hydroxamate-based
MMPIs had passed all published pre-clinical investigations and had
entered clinical trials with cancer patients [15]. Still, the MMP ﬁeld
was taken by surprise when these drugs failed in the clinic due to lack
of therapeutic efﬁcacy, poorer outcome, or unacceptable side effects
[5,9,23].
The design-ﬂaws of the clinical trials have been discussed in detail
elsewhere [5,9,23]. It has been concluded that the expectation of
successfully treating patients with advanced disease using these
inhibitors was unrealistic, as the decisive waves of metastasis had
most likely already occurred in these patients, and thus the MMPIs
would have been administered too late to make a difference.
However, even on the level of pre-clinical studies, some conceptual
limitations in experimental design and readouts could be identiﬁed
which have obscured the Janus-faced effects of MMPIs: the mouse
models chosen at the time often mixed tumor growth- with invasion-
related outcomes. In the attempt to use mouse models that “resemble
the clinical situation,” the effects of MMPIs on individual steps of
tumor growth and the metastatic cascade became extremely difﬁcult
to analyze [24]. Comprehensive data on micro-metastasis to a variety
of organs were not shown, so that the pro-metastatic effect of broad-
spectrum MMPIs in the liver, one of the most afﬂicted organs of
metastasis, escaped investigators for too long [24]. The message for
the ﬁeld was that more knowledge about the biology of MMPs and the
effects of MMP inhibition on aggressive cancer, especially metastasis,
had to be gained. This lesson has presented a particular challenge,
because as a direct result of the failure of the trials, funding and
interest in protease-related projects in cancer research lost consider-
able momentum.
Identiﬁcation of an increasing number of MMP molecules, as well
as the realization of the complexity of interactions between proteases
of different families, which actually had been pointed out rather early
[25], deepened our insight into the biology of MMPs in parallel with
the growing data from pre-clinical and clinical trials in the 1990s. This
knowledge was not integrated into experimental or clinical study
designs at the time, but has subsequently provided important insights
in interpreting the failure of the ﬁrst generation MMPIs.
3. Tissue homeostasis is sensitive to systemic protease
web-associated modulation
A decisive advance was the appreciation of the tumor micro-
environment as a major determinant of tumor progression [26,27].
The tumor microenvironment contains, in addition to various stromal
cells, the extracellular matrix (ECM), which is not only a scaffold for
the tissue, but also a reservoir of growth factors, cytokines, and ECM
components with cryptic biological functions [27]. The local
proteolytic balance inﬂuences the availability of all ECM-derived
extracellular signals and thereby modulates gene expression signa-
tures and cell behavior of both tumor and stroma cells. This ﬁne-
controlled signaling function of the ‘protease web’ controls tissue
homeostasis in each organ in normal physiology as well as during
disease (Fig. 1A). These local proteolytic networks in tissues
communicate with each other in the organism over a distance viathe circulatory system [14]. Cytokines, hormones [14], as well as
secreted protease inhibitors such as TIMP-1 [24] are information-bits
which are up- or down-regulated depending on the status of
homeostasis in the regional proteolytic network. Such signals are
sent to other tissues in the body via the proteolytic internet and may
induce speciﬁc responses that may determine the susceptibility of
the organism to disease [14]. The proteolytic internet articulates the
systemic impact of proteolysis-regulated homeostasis in individual
tissues or organs. The concept of the proteolytic internet also stresses
that non-glandular tissues can affect distant entities such as other
organs or circulating tumor cells [14]. Consequently, drastic as well as
very subtle changes in the proteolytic network by MMP inhibition
can induce systemic protease web-associated modulation (spam)
locally and can have consequences in the entire organism via the
proteolytic internet (Fig. 1B). The nature of undesired spam in local
networks or in the proteolytic internet can be deﬁned by examina-
tion of its consequences in gene expression signature via transcrip-
tomics or proteomics. Spam is decisive for the susceptibility of a
target tissue to tumor cells [14] and may well inﬂuence the success of
therapeutic intervention.
4. Spam in the local network by broad-spectrum MMP inhibition
Broad-spectrum inhibition of MMPs with the hydroxamate inhi-
bitor batimastat can promote liver metastasis of tumor cells in mice
[6,28]. This result was rather unexpected and provided ﬁrst hints for
the nature of MMP inhibition-induced spam [6]. At the time, we made
it a point to analyze liver tissue of batimastat-treated mice that had
never been exposed to tumor cells and sought to explain why this
would render the liver more susceptible to invading tumor cells [6].
Batimastat treatment induces overexpression of MMPs-2 and -9,
hepatocyte growth factor (HGF), which is also known as scatter factor
for tumor cells [29], basic ﬁbroblast growth factor (bFGF), angiogenin,
and caspase-1 [6]. The up-regulation of these pro-invasive and pro-
angiogenic factors could explain the observedpromotionofmetastasis.
More recently, in another experimental context, we found a
possible molecular mechanism for the increased susceptibility of the
liver to metastases upon broad-spectrum MMP inhibition: we
simulated elevated expression levels of tissue inhibitor of metallo-
proteinases-1 (TIMP-1), known to correlate with poor prognosis of
many human cancer types [30,31]. After gene transfer, mice over-
expressed TIMP-1 in the liver and exhibited high systemic levels of the
protein in the circulation. These effects were associated with a drastic
change of the gene expression signature in the liver, including
increases in the levels of HGF and other metastasis-promoting genes
[7]. This gene expression signature, which characterizes the spam in
this model (Fig. 1A), was compared with tumor-free liver samples
from patients with elevated TIMP-1 levels. The model and the human
samples showed a surprisingly high conformity of elevated pro-
metastatic gene expression [7]. In mice with elevated TIMP-1,
signaling through the tyrosine kinase receptor of HGF, cMet [32], is
markedly induced. The increased phosphorylation of cMet was
accompanied by elevation of HGF protein and mRNA as well as
accumulation of immuno-histochemically detectable cMet (but not
cMet mRNA) in the liver. While the source of the increased HGF levels
is still under investigation, we found that the increase of liver cell
surface-associated cMet is at least indirectly regulated by ADAM-10
[7]. Elevated cMet signaling induces the expression of several
downstream metastasis-promoting genes, including proteases such
as cysteine protease-cathepsins (CP), urokinase-type plasminogen
activator (uPA), and matriptase, which altogether create a pro-
metastatic environment [7,24] (Fig. 1A).
Kaplan et al. recently propagated the concept of the pre-metastatic
niche, which describes the evolution of advantageous environmental
conditions in the target organ of metastases before the tumor cells
actually invade [33]. In this concept, hematopoietic cells play the
Fig. 1. Spam-induction in regional proteolytic networks and in the proteolytic internet. (A) A regional proteolytic network, comprising the protease web (proteases, protease
inhibitors, the extracellular matrix (ECM), and effector molecules) and cells, dynamically regulates homeostasis in the healthy tissue. As an example, the effects of broad-spectrum
MMP inhibition on alterations of the local network are shown. Possible spam-ﬁltering agents are indicated. (B) Tissue homeostasis in the entire organism is suggested to be
maintained by the proteolytic internet [14], which communicates the status of regional proteolytic networks over a distance via the blood circulation. As an example, the effect of
MMP-9 ablation on the homeostasis of the bonemarrow is shown. The resulting IL-6-secretion affects the homeostatic balance of other organs [14]. A possible spam-ﬁltering strategy
which may suppress adverse effects on progression of metastasis is indicated. uPA: urokinase-type plasminogen activator, a serine protease often overexpressed in cancer [50];
ADAM-10: a disintegrin and metalloproteinase with many regulatory functions at the cell surface [21]; cMet: a tyrosine kinase receptor involved in invasion and metastasis [32].
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the proteolytic network in the liver by MMP inhibition led to the
formation of a pre-metastatic niche, which became evident when
mice with a TIMP-1-induced alteration of gene expression in the liver
were challenged by different tumor cells. The result was increased
metastasis with a very aggressive inﬁltrating phenotype as compared
to mice transduced with the control virus [7].
5. Spam is a general problem of broad-spectrum protease
inhibition
As mentioned above, the augmented proteolytic activity of CPs
was one spam created by high levels of TIMP-1 [7]. In an attempt to
prevent the TIMP-1-induced scattering of metastases in the liver
parenchyma by co-expression of cystatin C, a natural broad-spectrum
inhibitor of CPs, we recently discovered that changes in the
proteolytic network in the liver can massively change the pattern of
liver metastasis: while the total tumor burden of HT1080 ﬁbrosar-
coma cells in the livers remained the same, the metastatic cells were
now localized in large macro-metastatic foci [34]. This clearly
underlines the dramatic and quite general impact of microenviron-mental changes induced by protease inhibition on metastasis and the
problem of unforeseeable biological effects. Interestingly, these
difﬁculties are organ-speciﬁc, as we have found that lung colonies of
HT1080 cells were reduced when high levels of TIMP-1 were present
in the mouse, and we could see an additive effect of metastasis-
suppression upon co-expression of TIMP-1 and cystatin C in the host
[34]. Therefore, spam can have different consequences in different
organs. It is important to note from these data that also broad-
spectrum inhibition of a totally different protease family, namely, the
cysteine protease-cathepsins, which are considered an important
target for cancer therapy [3], harbors the potential to cause problems
in the clinic, as ablation of the cysteine protease cathepsin B can
lead to altered levels and distribution of the carboxymonopeptidase
cathepsin X [35].
6. Promotion of metastasis by MMP ablation-induced spam in
functional genetic mouse models
One of themajor conclusions of the failure of the ﬁrst generation of
MMPIs in the clinic was to employ more speciﬁc agents. The intention
was to effectively inhibit only those MMPs which clearly play a
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suppress tumor-progression or are essential for maintenance of
homeostasis in healthy tissue [8]. The pre-requisite for such an
approach is detailed knowledge about the role of each MMP in
different phases of tumor progression in every organ.
Functional genetics is currently the only technique that can
speciﬁcally eliminate one protease function from the proteolytic
network. Knockout mice provide information about the ablated gene
in the host tissue during embryogenesis and development as well as
in the response of the organism to disease challenges imposed by
transplantation of pathogens or tumor cells, or by crossing with
genetically engineered disease models (e.g., tumor models as
reviewed by Frese and Tuveson [36]). Knockout mice showing an
overt lethal or disease phenotype imply a direct function of the
ablated gene in the affected (patho-)physiology, most likely due to
lack of compensation by other gene products. However, when
knockout mice survive with an obviously healthy phenotype, the
lack of the gene must have been compensated, and new homeostatic
tissue environments must have been established [14]. Such compen-
sation is very likely when proteases are knocked out: evolution has
selected for a large set of proteases in the genome (1.7% of the human
genome code for proteases [8]), indicating the importance of these
protein families for life. In addition, many of the proteases overlap in
their substrate speciﬁcity [25], indicating that the biological functions
executed by these enzymes are so essential that redundancy became
an asset in natural selection. Also, more than 10 years ago, DeClerck
et al. pointed out the complex interactions between MMPs, serine,
cysteine, and aspartyl proteases [25]. These complex interrelations
render target identiﬁcation and validation extremely difﬁcult, which
has led to discordant views of the roles of particular proteases or
protease inhibitors in tumor progression or metastasis. Conﬁdence
that we are in ‘an era where controlled experiments can be performed
in complex mammalian models’ [37] may be misplaced. On the
contrary, we should be wary about drawing easy general conclusions
about whether or not a protease is pro- or anti-metastatic on the basis
of gene knockout models. Nevertheless, if we carry these models into
the era of systems biology via appreciation of the protease web, they
bear great potential for our understanding of cancer and cancer
therapies [14].
Functional genetic mouse models are indeed promising tools for
investigation of the proteolytic internet, i.e., they help to reveal the
communication between the different local organ- or molecular
polymorphism-speciﬁc proteolytic networks in an organism [14]. A
pre-requisite for taking advantage of this tool is a systematic analysis
of the gene expression signature present in the different organs/
tissues of these mice. This would facilitate the interpretation of what
might at ﬁrst sight appear to be surprising or conﬂicting results. In a
recent critical appraisal of such results, evidence for the inﬂuence of
gender [38], the mouse strain employed [39], or the organ site [40,41]
on the effects of MMP ablation on tumorigenesis or metastasis was
summarized [14]. It was shown that ablation of a single MMP (MMP-
9) modulates the expression of many metastasis-associated genes in
the liver and in bone marrow [14]. Loss of MMP-9 led to an increase of
IL-6 in the circulation, acting as a pro-metastatic factor on circulating
tumor cells, which more efﬁciently colonized the liver [14] (Fig. 1B).
Currently, we are identifying the MMP-9-responsive signaling-path-
way that led to IL-6 up-regulation (Krüger et al., unpublished results).
From this, it is evident that the pro-metastatic effect of MMP-9
ablation is in fact an indirect consequence of homeostatic adaptation
of the bone marrow signaling environment to the missing gene
product. This realization cannot lead to the conclusion that MMP-9 is
an anti-target. Indeed, all tested speciﬁc synthetic MMP-9 inhibitors
[42,43] or knockdown of MMP-9 in tumor cells [44] clearly shows the
importance of MMP-9 for liver metastasis. Analysis of the spam in the
aforementioned models [38-41] would be expected to reveal the
pathways involved.7. Anti-metastatic potential of spam-ﬁltering agents
7.1. Highly speciﬁc MMPIs
In point of fact, the development of more speciﬁc MMPIs
progressed at much greater pace than the deﬁnition of individual
MMPs as relevant targets. Modern biophysical techniques, including
nuclear magnetic resonance, X-ray crystallography, and isothermal
titration experiments, led to an increasingly better understanding of
the speciﬁc structural and dynamic features of MMPs that can be
exploited in order to design highly speciﬁc synthetic inhibitors [13].
Application of these techniques resulted in a growing set of inhibitors
with high speciﬁcity for individual MMPs [12,13,45]. The key change
of strategy in these efforts was to search for alternatives to usingmere
Zn-chelating activity and to further exploit the structure of MMPs in
the catalytic domain and also the exosites of the enzymes [12,13]. On
the basis of these alternatives, a series of sub-type selective MMPIs
were designed, including those with an alternative Zn-binding group
(with carboxylate, substituted cyclic compounds, pyrimidine-based
thiol, and substituted cyclic residues [12]) or even non-competitive
inhibitors without Zn-binding group [13].
In vivo, some of these compounds have already proved to be
effective to avoid pro-metastatic activity of spams: this is the case for
the pyrimidine-2,4,6-trione-type inhibitors Ro28-2653 and Ro206-
0222 have a higher speciﬁcity towards MMP-2, MMP-9, and MMP-14
[46]. We could show a signiﬁcant correlation between MMP-9-
speciﬁcity of these inhibitors and their anti-metastatic efﬁcacy in the
liver [42]. In respect to spams that may occur during speciﬁc MMP-9
inhibition [14], it is likely that the systemic levels and bioavailability
of MMP-9 inhibitors was sufﬁcient to block the IL-6-induced MMP-9
expression by liver-invading tumor cells (Fig. 1A). Indeed, we already
have initial indications that bone marrow homeostasis can be
modulated by synthetic MMP-9 speciﬁc inhibitors in the same way
as upon MMP-9 ablation (Krüger et al., unpublished results). Still, it is
apparent that effective inhibition of MMP-9 in circulating tumor cells
by high levels of a highly speciﬁc synthetic inhibitor can avoid the
biological effects of spam [42-44]. Similar success was achieved with
the MMP-2, -9, and -14-selective N-sulfonylamino acid derivate MMI-
166 which inhibited experimental metastasis to the liver [47].
A fundamentally different MMPI is SB-3CT [48]. It is the ﬁrst
mechanism-based MMPI which achieves remarkable level of selec-
tivity for the gelatinases MMP-2 and -9 due to the speciﬁc
coordination of its thiirane group with the residues in the active site
of these proteases [12]. This inhibitor achieved the highest anti-
metastatic efﬁcacy in the T-cell lymphoma liver metastasis model as
compared to all other tested MMPIs [43]. The number and size of liver
metastases were markedly reduced, demonstrating the efﬁcacy of
gelatinase-directed synthetic inhibitors on extravasation and invasion
of metastatic tumor cells and outgrowth of the foci [43]. However,
treatment of mice with SB-3CT also leads to induction of spam, which
is again represented by increased IL-6 levels in the circulation (Krüger
et al., unpublished observation). The consequential induction of
MMP-9 expression in circulating tumor cells [14] was obviously
counteracted by effective inhibition of tumor cell-derived MMP-9 by
SB-3CT [43].
7.2. Spam-directed therapy with a speciﬁc tyrosine kinase inhibitor
As mentioned above, spam can encompass not only proteases,
which may promote the invasive and metastatic potential of tumor
cells, but also a multitude of pro-metastatic factors such as adhesion
molecules, cytokines, growth factors, and growth factor receptors
[7,34]. One of the most potent pro-metastatic signaling systems is the
cMet tyrosine kinase pathway [49]. In the traditional view, this
pathway is activated in tumor cells, conferring pro-migratory and pro-
invasive features to the cell [49]. However, alterations of the cMet
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interplay between tumor cells and host tissue. We have found that
induction of cMet signaling in the host by unselective MMP inhibition
totally altered the local proteolytic network in the liver, rendering this
site more susceptible to metastases [7]. Since cMet signaling is such a
key event in the maintenance of cellular homeostasis, we hypothe-
sized at the time whether this spam could be avoided just by
inhibiting the tyrosine function of cMet. Indeed, administration of a
highly speciﬁc synthetic cMet inhibitor prevented the pro-metastatic
effect of broad-spectrum MMP inhibition by TIMP-1 [7] (Fig. 1A). Of
course, this deﬁnitely does not mean that broad-spectrum MMPs
could be pursued when combined with a speciﬁc cMet inhibitor.
However, this example demonstrates that knowledge about the key
molecules of a spam (in this case cMet) can lead to anti-metastatic
treatment strategies, in which speciﬁc agents that can reverse adverse
effects of a spam can be combined with speciﬁc protease inhibition
(Fig. 1).
7.3. Spam-ﬁltering by targeting uPA
The drastic change of metastasis pattern in livers of mice with
elevated TIMP-1/cystatin C levels was correlated with another spam
that involved signiﬁcant up-regulation of tissue-type plasminogen
activator (tPA) during liver metastasis. This serine protease is known
to be involved in metastasis formation, possibly by regulating ﬁbrin
deposition in the vasculature [50], and is regulated by its highly
speciﬁc natural inhibitor PAI-2 [51]. Simultaneous overexpression of
secreted PAI-2 in the host efﬁciently inhibited both the pro-
metastatic and metastatic pattern-changing spam induced by TIMP-
1 alone or by the TIMP-1/cystatin C-combination [34]. The former
effect was likely due to inhibition of uPA, part of the TIMP-1-induced
spam (see above and [7]), the latter due to inhibition of tPA, part of
the TIMP-1/cystatin C-induced spam [34]. These observations
demonstrate that if key pro-metastatic molecules of spams are
identiﬁed (here uPA and tPA), their speciﬁc inhibition may be
feasible (Fig. 1A). Indeed, in all models summarized here, highly
speciﬁc synthetic uPA inhibitors, which are much easier to design
than MMPIs, are very efﬁcient in inhibiting liver and lung metastasis
[51–53], indicating that very speciﬁc intervention with individual
proteases of the network has a much increased chance to become a
successful anti-metastatic therapeutic approach.
7.4. A control-theoretic approach to the spam problem and possible
application in functional genetic mouse models
In Fig. 2 we depict a conceptual situation as follows: Homeostasis
within the original organ (“regional proteolytic network 0”) is
represented schematically by an “inner” regulatory loop. Suppose
that, in a certain phase of the disease, the level of a particular MMP, for
example, MMP-9, reaches a pro-metastatic range, conducive to
invasive tumor progression [44]. The effects of any treatment
intervention within the original organ (“regional proteolytic network
0”) intended to inhibit the unhealthy MMP are modulated by the
“inner” regulatory loop. MMP inhibition needs to be effective and
speciﬁc enough so that the resulting MMP levels in the original organ
(0) are maintained in a non-metastatic range, taking into account the
inner regulatory loop.
However, even an MMP inhibition strategy that is sufﬁciently
speciﬁc in the original organ (0) can still lead to expression of
metastasis-promoting molecules in other organs (n), via spam-
induced interactions interfering with normal homeostasis in those
organs (“regional proteolytic network n”) [14]. These interactions are
schematically represented in Fig. 2 by an “outer” regulatory loop. The
goal in a future therapy is thus to avoid such secondary pro-metastatic
effects as well by designing the biological analog of a controller that
takes into account both inner and outer regulatory loops.In order to develop a systematic strategy for designing a biological
controller, we would like to take this opportunity in this review to
describe the situation using the concept of a state vector X as is
customary in engineering control theory. Thus, the MMPs are
numbered by an index i=1,2,3…,24 for 24 MMPs, and the homeo-
static state in some organ (n) is denoted X(n), where n=0 for the
original organ. The components of the state vector X are denoted Xi
(n). For simplicity, let us suppose that for each organ, each local MMP
level is characterized as either pro-metastatic (Xi(n)=1) or healthy
(Xi(n)=0). A healthy state in an organ n thus corresponds to the
statement
XðnÞ ¼H nð Þ; orXi nð Þ¼Hi
where Hi=0 for all MMPs. An unhealthy state in an organ n
corresponds to the statement
X nð Þ¼U nð Þ; or in components Xi nð Þ¼Ui
where Ui=1 for at least one MMP in that organ (there could be
several pro-metastatic components).
Suppose now that one of the MMPs, say i=9 for MMP-9, initially
has a pro-metastatic level in the original organ, for example, at the
time-point before anti-metastatic treatment. This assumption implies
that X9(0)=1. The effect of this treatment (e.g., inhibition) on the
state is represented as a controller T, which induces not only a change
in the state vector in the original organ (0), but also in all other organs
via the outer regulatory loop. This induced change is represented
abstractly as a transition
X nð ÞYT X nð Þð Þ:
If the treatment is effective and speciﬁc in the original organ (0), then
T(X(0))=H(0) (healthy state) even for MMP-9 in our example.
However, it still might happen that, via spam in the outer regulatory
loop, the treatment induces secondary, pro-metastatic levels of some
other MMP (labeled j, say j=2 for MMP-2) in some distant organ n,
such as the liver. We represent this purely hypothetical situation by
writing
T X liverð Þð Þ¼U liverð Þ;withU2 liverð Þ¼ 1:
(In general, there could be more than one secondary induced pro-
metastatic MMP level in an organ or different induced pro-metastatic
MMP levels in different organs, of course.)
Up to here, the control theory description we have given has been
merely a restatement of the original problem in engineering notation.
However, it may be possible to infer some practical research
strategies from this picture; for example, if the effects of treatment
interventions on homeostasis in distant organs depend only on the
local proteolytic network in the originally treated organ of metastasis
and if the outer regulatory loop in a diseased individual is sufﬁciently
similar to the outer regulatory loop in a healthy individual, then we
could represent the effects of treatment in a distant organ (n) in
matrix notation by Sij(n):
Tj nð Þ =
X24
i=1
Sij nð ÞXi 0ð Þ
where Sij(n) is a matrix of binary numbers, since we have assumed
that the state vectors are binary numbers.
One potential payoff of this approach is that if the above simplifying
assumptions were satisﬁed, then one might be able to infer the matrix
of binary numbers Sij(n) by a series of conceptually simple experi-
ments in functional genetic mouse models [14] and thus isolate the
most critical interactions resulting from the outer regulatory loop,
which in this language are those with signals Tj(n)=1.
Fig. 2. Cybernetic model of MMP inhibition combined with spam-ﬁltering agents. The regional level of tissue homeostasis in “regional proteolytic networks” is represented as an
inner regulatory loop, which, however, is coupled via the circulatory system to other regional proteolytic networks (outer regulatory loop, proteolytic internet) with other organs
such as the liver. Hence, inhibition ofMMPs intended to affect one “regional network,” can, evenwhen the inhibitors are highly speciﬁc, induce pro-metastatic environments in other
organs such as the liver, due to their differing regional homeostasis. The situation represented here is as follows: Suppose that theMMPs are numbered by an index i=1,24 for the 24
human MMPs. Inhibition of the i-th MMP (say MMP-9) induces a signal Sij(0) (say one for an elevated level and zero for the level of healthy tissue). Here, the index j stands for the
induced level of the j thMMP. If inhibition is speciﬁc enough, then all Sij(0) might be in a healthy or at least non-metastatic range. However, the inhibition induces a signal not only in
the original organ (or regional network) labeled “0,” with primary cancer cells, but also induces via spam a signal Sij(n) in other organs, labeled “n.” If one or more of the signals in
organ n are unfavorable Sij(n)=1, then there could be a pro-metastatic environment due to the j-th MMP. This effect will then be controlled by spam suppressors.
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ventions will propagate forward via the proteolytic internet, the goal
of negating any process leading to a pro-metastatic environment is
analogous to an inverse propagation of any signals Tj(n)=1. If this
goal could be achieved using inferences on a matrix Sij(n) gained by
means of conceptually simple experiments, then one might progress
more rapidly towards effective treatments.
8. Concluding remarks and perspectives
Homeostasis in the tissue or in the tumor microenvironment is
essentially dependent on the protease web and the impact of distant
local proteolytic networks via the proteolytic internet [14]. Therefore,
any broad-spectrum or highly speciﬁc functional genetic or pharma-
cological blockade of protease function will elicit considerable
systemic effects. Such systemic protease web-associated modulation
(spam) may either be neutral, beneﬁcial, or harmful with respect to
the desired inhibition of tumor cell invasion and metastasis. Whether
or not this new gene expression signature renders organs more or less
susceptible to metastasis can nowadays easily be monitored in
appropriate experimental settings in vivo [24], which need to include
systems biology analysis of the spam. As there are still no drugs
available which speciﬁcally inhibit steps of metastasis, and some
individual MMPs may be excellent targets for the prevention of organ
colonization [44], it is worthwhile to carefully investigate the nature
of MMP inhibition-induced spam. The aim of this endeavor is to
prevent adverse secondarymolecular effects induced by speciﬁc MMPinhibition as reported here (Fig. 1). A second consideration is that the
elucidation of the complex biology of MMP inhibition is lagging
behind the fast and ever more sophisticated development of highly
speciﬁc synthetic MMPIs or antibodies. In order to take advantage of
their anti-proteolytic efﬁcacy, which may be essential to prevent the
basic invasive steps of metastasis, it will be necessary and it is, as
shown here, in principle possible to identify molecules which can be
targeted by other compounds in order to avoid spam in local
proteolytic networks or its distribution via the proteolytic internet.
Extensive transcriptomics and proteomics analyses will support this
endeavor. This kind of analysis will also be necessary with regard to
personalized health care, which possibly will have to account for
individual differences in gene expression signatures induced by a
therapeutic procedure. MMP inhibition is likely to be crucial for a
speciﬁc anti-metastatic therapy, and research on MMP inhibition
could be in the vanguard for the application of systems biology for the
design of novel anti-metastatic treatment strategies.
In the future, it may be possible to apply a control-theoretic
approach such as that presented in section 7.4 to conceive systematic
experiments with the goal of avoiding spam, i.e., negating any process
leading to a pro-metastatic environment in a secondary organ, with
the objective of progressing more rapidly towards effective treat-
ments. One potential approach involves speciﬁc inhibition of key pro-
metastatic molecules of spams (e.g., uPA, tPA, or IL-6) or, in general
terms, identiﬁcation of molecules and secondary targeting by other
compounds to avoid spam in local proteolytic networks or its
distribution via the proteolytic internet.
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